During the past decade, Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials sponsored and "III. Medizinische Klinik Mannheim" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie" #1 collaborator was "ADIR, a Servier Group company" with 1 trials as a collaborator, "Arbeitsgruppe Lebermetastasen und Tumoren" with 1 trials as a collaborator, "Australasian Gastro-Intestinal Trials Group" with 1 trials as a collaborator, "Cancer Research UK" with 1 trials as a collaborator and "Fondation Francaise de Cancerologie Digestive" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie" are "Lymphoma" (2 trials), "Arthritis, Rheumatoid" (1 trials), "Colorectal Cancer" (1 trials), "Gastric Cancer" (1 trials) and "Giant Cell Arteritis" (1 trials). Many other conditions were trialed in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie" are "Drug" (10 trials), "Biological" (4 trials), "Procedure" (3 trials), "Radiation" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (3 trials), "fluorouracil" (2 trials), "leucovorin calcium" (2 trials), "neoadjuvant therapy" (2 trials) and "radiation therapy" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Erlangen; Medizinische Klinik 3; Rheumatologie und Immunologie, 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".